Abstract
Olanzapine/samidorphan (LYBALVI®) is a useful treatment option for patients with schizophrenia or bipolar I disorder who could benefit from the antipsychotic efficacy of olanzapine, but for whom the potential for olanzapine-associated weight gain might otherwise preclude its use. In clinical trials (ENLIGHTEN-1 and ENLIGHTEN-2) in patients with schizophrenia, olanzapine/samidorphan had similar efficacy to olanzapine; samidorphan did not appear to impact the antipsychotic efficacy of olanzapine. In addition, olanzapine/samidorphan led to significantly less weight gain than olanzapine in ENLIGHTEN-2. Sustained benefits of olanzapine/samidorphan were evident with longer-term therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
